GlassScriptPhysician profile
Debra Buchan
NPI 1689618498
$2,853.62
in general payments reported to CMS, 2019-2025
24 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $162 · 2022: $11.71 · 2023: $513 · 2024: $717 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.36 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $419.55 | 2019-2025 | |
| Abbvie INC. | $282.31 | 2019-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $268.18 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $257.93 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $235.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $216.56 | 2019-2024 | Veozah |
| Amgen INC. | $215.88 | 2019-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $166.35 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $140.84 | 2019-2024 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.17 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $70.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $64.81 | 2019-2025 | |
| Kyowa Kirin, INC. | $56.02 | 2025 | |
| Merck Sharp & Dohme LLC | $55.89 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Corcept Therapeutics | $49.96 | 2025 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $40.58 | 2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $33.79 | 2019 | |
| Phathom Pharmaceuticals, INC. | $33.65 | 2024-2025 | Voquezna |
| Ibsa Pharma INC. | $30.96 | 2020-2023 | Tirosint, Licart |
| Janssen Pharmaceuticals, INC | $29.00 | 2019 | |
| Genentech USA, INC. | $27.87 | 2019-2020 | |
| Abbott Laboratories | $24.81 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $15.87 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2024 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Buchan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.